Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
This is a multi-center, 20-week study of inosine treatment.
Study Objectives and Endpoints The primary objective of the study is to determine the safety
and tolerability of oral administration of inosine (administered daily) dosed to moderately
elevate serum urate over 20 weeks.
The primary outcome measures will be
1. Safety, as measured by adverse events
2. Tolerability, defined as the ability of subjects to complete the entire 20-week study.
As an exploratory objective, we will test the feasibility and utility of a smartphone
application for monitoring symptoms and disease progression in patients with amyotrophic
lateral sclerosis (ALS).